Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The Company is developing therapeutic interventions for anxiety, depression, alzheimer"s disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity, and diabetes.
Website: neurocrine.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 38.6%. The revenue growth dynamics is stable

Profitability: LTM EBITDA margin is positive, +23.9%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 0% of quarters (showing a gain of -$0.46 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 2.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 53.7% higher than minimum and 13.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 8.8x by EV / Sales multiple , the company can be >100% undervalued

Insiders: For the last 3 months insiders sold company shares on $11.8 mln (-0.087% of cap.)

Key Financials (Download financials)

Ticker: NBIX
Share price, USD:  (0.0%)134.51
year average price 130.04  


year start price 115.02 2025-02-14

min close price 87.54 2025-04-08

max close price 155.63 2025-12-10

current price 134.51 2026-02-13
Common stocks: 95 800 000

Dividend Yield:  0.0%
FCF Yield LTM: 2.5%
EV / LTM EBITDA: 11.2x
EV / EBITDA annualized: 4.6x
Last revenue growth (y/y):  > +200.0%
Last growth of EBITDA (y/y):  +152.6%
Historical revenue growth:  +38.6%
Historical growth of EBITDA:  +36.1%
EV / Sales: 2.7x
Margin (EBITDA LTM / Revenue): 23.9%
Fundamental value created in LTM:
Market Cap ($m): 12 886
Net Debt ($m): -298
EV (Enterprise Value): 12 588
Price to Book: 4.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-26prnewswire.com

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia

2026-01-22zacks.com

Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive?

2026-01-21prnewswire.com

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results

2025-12-22reuters.com

Neurocrine's movement disorder treatment fails late-stage trial

2025-12-16seekingalpha.com

Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript

2025-12-02seekingalpha.com

Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

2025-11-27zacks.com

Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now

2025-11-11zacks.com

Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice

2025-10-28seekingalpha.com

Neurocrine Biosciences, Inc. (NBIX) Q3 2025 Earnings Call Transcript

2025-10-28zacks.com

Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475
fillingDate 2025-10-28 2025-07-30 2024-10-30 2024-08-01 2024-05-01 2023-10-31 2023-08-01 2023-05-03 2022-11-01
acceptedDate 2025-10-28 16:03:58 2025-07-30 16:04:04 2025-02-10 16:51:08 2024-10-30 07:04:11 2024-08-01 07:04:01 2024-05-01 07:03:13 2024-02-09 17:29:13 2023-10-31 07:02:45 2023-08-01 07:03:07 2023-05-03 07:34:21 2023-02-09 16:02:45 2022-11-01 16:10:37 2022-02-11 17:11:18 2021-02-05 16:19:49
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 795M 688M 2 355M 622M 590M 515M 1 887M 499M 453M 420M 1 489M 388M 1 134M 1 046M
costOfRevenue 14M 11M 34M 8M 16M 13M 40M 11M 12M 9M 23M 6M 14M 10M
grossProfit 781M 676M 2 321M 614M 575M 502M 1 847M 488M 441M 412M 1 466M 382M 1 119M 1 036M
grossProfitRatio 0.982 0.984 0.987 0.974 0.975 0.978 0.975 0.98 0.984
researchAndDevelopmentExpenses 250M 244M 731M 195M 185M 154M 565M 142M 146M 140M 464M 108M 328M 275M
generalAndAdministrativeExpenses 0 0 816M 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 191M 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 292M 286M 1 007M 234M 242M 243M 888M 204M 222M 243M 753M 186M 583M 433M
otherExpenses 300 000 0 13M 1 000 000 3M -89M 144M 0 0 144M 0 0 105M 165M
operatingExpenses 542M 531M 1 751M 430M 427M 397M 1 597M 346M 368M 382M 1 217M 294M 1 017M 873M
costAndExpenses 556M 542M 1 785M 438M 442M 410M 1 636M 358M 379M 391M 1 240M 300M 1 031M 883M
interestIncome 22M 21M 91M 0 0 0 0 16M 0 0 11M 0 0 0
interestExpense 0 0 127M 0 0 1M 5M 1M 1M 1M 7M 1M 26M 33M
depreciationAndAmortization 8M 7M 27M 7M 7M 6M 21M 6M 5M 144M 16M 4M 11M 9M
ebitda 300M 153M 640M 191M 155M 112M 416M 141M 74M 30M 265M 92M 138M 148M
ebitdaratio 0.377 0.222 0.308 0.263 0.216 0.283 0.163 0.071 0.237
operatingIncome 239M 146M 571M 184M 148M 105M 251M 141M 74M -114M 249M 88M 103M 163M
operatingIncomeRatio 0.301 0.212 0.295 0.251 0.204 0.283 0.163 -0.272 0.226
totalOtherIncomeExpensesNet 53M 14M -85M 7M -47M -71M 81M -25M 49M 11M -35M 10M -1M -56M
incomeBeforeTax 292M 160M 486M 190M 99M 35M 332M 116M 122M -103M 214M 98M 101M 107M
incomeBeforeTaxRatio 0.367 0.232 0.306 0.167 0.067 0.232 0.269 -0.246 0.252
incomeTaxExpense 82M 52M 145M 61M 34M -9M 82M 33M 26M -27M 59M 29M 12M -301M
netIncome 210M 108M 341M 130M 65M 43M 250M 83M 96M -77M 155M 69M 90M 407M
netIncomeRatio 0.264 0.156 0.209 0.11 0.084 0.167 0.211 -0.182 0.177
eps 2.11 1.09 3.4 1.28 0.64 0.43 2.56 0.85 0.98 -0.79 1.61 0.72 0.95 4.37
epsdiluted 2.04 1.06 1.24 0.63 0.42 0.82 0.95 -0.79 0.69
weightedAverageShsOut 99M 99M 100M 101M 101M 100M 98M 98M 98M 97M 96M 96M 95M 93M
weightedAverageShsOutDil 103M 101M 104M 104M 104M 104M 101M 101M 100M 97M 99M 99M 98M 98M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-10 2024-02-09 2023-02-09 2022-02-11 2021-02-05
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -36M -5M 4M -26M -33M
ebit 613M 395M 249M 127M 140M
nonOperatingIncomeExcludingInterest -42M -144M 0 -25M 24M
netIncomeFromContinuingOperations 341M 250M 155M 90M 407M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 341M 250M 155M 90M 407M
epsDiluted 3.29 2.47 1.56 0.92 4.16

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475
fillingDate 2025-10-28 2025-07-30 2024-10-30 2024-08-01 2024-05-01 2023-10-31 2023-08-01 2023-05-03 2022-11-01
acceptedDate 2025-10-28 16:03:58 2025-07-30 16:04:04 2025-02-10 16:51:08 2024-10-30 07:04:11 2024-08-01 07:04:01 2024-05-01 07:03:13 2024-02-09 17:29:13 2023-10-31 07:02:45 2023-08-01 07:03:07 2023-05-03 07:34:21 2023-02-09 16:02:45 2022-11-01 16:10:37 2022-02-11 17:11:18 2021-02-05 16:19:49
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 340M 264M 233M 349M 140M 396M 251M 294M 160M -90M 263M 212M 341M 187M
shortTermInvestments 775M 712M 843M 879M 899M 814M 781M 801M 817M 1 139M 726M 587M 371M 614M
cashAndShortTermInvestments 1 115M 976M 1 076M 1 228M 1 039M 1 211M 1 032M 1 095M 977M 895M 989M 799M 711M 801M
netReceivables 728M 596M 479M 481M 468M 451M 439M 418M 388M 392M 350M 301M 186M 157M
inventory 69M 57M 57M 46M 43M 37M 38M 29M 32M 33M 35M 37M 31M 28M
otherCurrentAssets 246M 121M 112M 122M 120M 101M 98M 555M 520M 538M 79M 68M 46M 30M
totalCurrentAssets 2 158M 1 749M 1 725M 1 877M 1 670M 1 799M 1 607M 1 650M 1 497M 1 433M 1 454M 1 206M 973M 1 016M
propertyPlantEquipmentNet 566M 584M 592M 337M 343M 346M 347M 150M 149M 147M 146M 151M 156M 127M
goodwill 0 0 6M 0 6M 0 0 0 0 0 0 0 0 0
intangibleAssets 36M 37M 37M 35M 34M 34M 36M 35M 37M 37M 37M 0 0 0
goodwillAndIntangibleAssets 36M 37M 42M 35M 34M 34M 36M 35M 37M 37M 37M 0 0 0
longTermInvestments 118M 961M 864M 771M 789M 872M 849M 588M 516M 380M 402M 458M 624M 265M
taxAssets 369M 537M 486M 454M 420M 378M 363M 383M 379M 337M 306M 319M 315M 319M
otherNonCurrentAssets 1 019M 22M 10M 62M 50M 43M 50M 43M 36M 25M 25M 11M 4M 6M
totalNonCurrentAssets 2 107M 2 141M 1 994M 1 658M 1 635M 1 673M 1 644M 1 198M 1 117M 927M 915M 938M 1 100M 719M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 4 266M 3 890M 3 719M 3 535M 3 305M 3 472M 3 251M 2 848M 2 613M 2 360M 2 369M 2 143M 2 073M 1 735M
accountPayables 120M 105M 110M 96M 107M 87M 133M 94M 0 0 67M 0 52M 39M
shortTermDebt 0 0 0 0 35M 294M 170M 170M 170M 0 169M 169M 0 0
taxPayables 0 26M 0 0 35M 25M 24M 73M 0 0 9M 0 0 0
deferredRevenue 0 0 0 0 0 25M 0 -94M 0 0 0 0 0 0
otherCurrentLiabilities 518M 416M 298M 334M 221M 307M 261M 522M 413M 374M 225M 316M 133M 91M
totalCurrentLiabilities 638M 546M 508M 430M 399M 713M 655M 692M 583M 374M 538M 485M 246M 187M
longTermDebt 428M 439M 0 251M 256M 253M 0 86M 89M 260M 0 97M 335M 318M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 196M 210M 166M 135M 141M 121M 106M 69M 89M 41M 30M -56M 12M 10M
totalNonCurrentLiabilities 624M 649M 621M 386M 397M 373M 365M 155M 178M 301M 123M 114M 453M 422M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 439M 455M 251M 292M 253M 258M 86M 89M 90M 94M 97M 105M 94M
totalLiabilities 1 262M 1 196M 1 129M 816M 796M 1 086M 1 019M 846M 760M 675M 661M 599M 699M 609M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000
retainedEarnings 294M 85M 29M 81M -49M -114M -157M -305M -388M -483M -407M -496M -636M -725M
accumulatedOtherComprehensiveIncomeLoss 13M 13M 6M 15M 3M 3M 7M -2M -1M -3M -8M -14M -2M 2M
othertotalStockholdersEquity 2 696M 2 597M 2 623M 2 555M 2 496M 2 309M 2 242M 2 171M 2 054M
totalStockholdersEquity 3 004M 2 694M 2 590M 2 719M 2 509M 2 386M 2 232M 2 002M 1 853M 1 685M 1 708M 1 545M 1 374M 1 126M
totalEquity 3 004M 2 694M 2 590M 2 719M 2 509M 2 386M 2 232M 2 002M 1 853M 1 685M 1 708M 1 545M 1 374M 1 126M
totalLiabilitiesAndStockholdersEquity 4 266M 3 890M 3 535M 3 305M 3 472M 2 848M 2 613M 2 360M 2 143M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 4 266M 3 890M 3 719M 3 535M 3 305M 3 472M 3 251M 2 848M 2 613M 2 360M 2 369M 2 143M 2 073M 1 735M
totalInvestments 893M 1 673M 1 707M 1 650M 1 689M 1 686M 1 630M 934M 990M 1 139M 1 128M 1 045M 995M 879M
totalDebt 428M 439M 455M 251M 292M 547M 428M 256M 259M 260M 263M 266M 440M 412M
netDebt 88M 175M 222M -98M 152M 151M 177M -38M 99M 350M 0 54M 100M 225M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-10 2024-02-09 2023-02-09 2022-02-11 2021-02-05
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 479M 439M 350M 186M 157M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 0 0
totalPayables 110M 133M 76M 52M 39M
otherPayables 0 0 9M 0 0
accruedExpenses 100M 90M 67M 61M 57M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 455M 258M 94M 105M 94M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 555M 2 382M 2 122M 2 011M 1 850M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX NBIX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475 914 475
fillingDate 2025-10-28 2025-07-30 2024-10-30 2024-08-01 2024-05-01 2023-10-31 2023-08-01 2023-05-03 2022-11-01
acceptedDate 2025-10-28 16:03:58 2025-07-30 16:04:04 2025-02-10 16:51:08 2024-10-30 07:04:11 2024-08-01 07:04:01 2024-05-01 07:03:13 2024-02-09 17:29:13 2023-10-31 07:02:45 2023-08-01 07:03:07 2023-05-03 07:34:21 2023-02-09 16:02:45 2022-11-01 16:10:37 2022-02-11 17:11:18 2021-02-05 16:19:49
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 210M 108M 341M 130M 65M 43M 250M 83M 96M -77M 155M 69M 90M 407M
depreciationAndAmortization 8M 7M 27M 7M 7M 6M 21M 6M 5M 5M 16M 4M 11M 9M
deferredIncomeTax 168M -37M -123M -35M -41M -16M -57M -4M -42M -32M 19M 9M 4M -311M
stockBasedCompensation 54M 53M 196M 42M 43M 45M 194M 48M 69M 40M 173M 43M 134M 100M
changeInWorkingCapital 63M -39M -19M 4M -86M -32M 28M 46M 93M -58M -67M -16M 17M -38M
accountsReceivables -132M -80M -40M -13M -18M -11M -89M -30M 4M -42M -162M -22M -28M -31M
inventory -12M 2M -19M -3M -5M 1M 5M 3M 2M 2M -3M -8M -3M -11M
accountsPayables 56M 16M 29M 39M -60M -19M 64M 124M 16M 7M 115M 0 57M 27M
otherWorkingCapital 152M 23M 11M -19M -4M -3M 48M -51M 71M -24M -17M 14M -9M -24M
otherNonCashItems -275M 11M 174M 11M 217M 169M -47M 34M -41M -4M 45M -10M 800 000 61M
netCashProvidedByOperatingActivities 228M 102M 595M 158M 65M 130M 390M 212M 180M -125M 339M 99M 257M 229M
investmentsInPropertyPlantAndEquipment -13M -13M -38M -8M -12M -11M -28M -8M -7M -9M -17M 0 -23M -11M
acquisitionsNet 0 0 0 0 0 0 0 90M 7M -2M -43M 0 0 0
purchasesOfInvestments -409M -315M -1 056M -233M -192M -320M -1 411M -363M -324M -238M -629M -134M -805M -736M
salesMaturitiesOfInvestments 225M 299M 968M 265M 175M 276M 972M 273M 205M 204M 511M 71M 698M 751M
otherInvestingActivites 0 0 0 -17M -44M -90M -7M 2M 2M
netCashUsedForInvestingActivites -197M -29M 25M -28M -55M -97M -126M -42M -61M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 46M 14M 26M 16M 70M 19M 0 8M 0
commonStockRepurchased 0 -18M -300M 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 26M -309M 70M 19M 0 0 11M
netCashUsedProvidedByFinancingActivities 46M -3M 26M -293M 70M 19M 3M 8M 11M
effectOfForexChangesOnCash -200 000 200 000 0 300 000 0 0 300 000 0 0 0 -1M 0 0 0
netChangeInCash 76M 70M -18M 217M -257M 145M -12M 134M 57M -159M -73M 49M 154M 75M
cashAtEndOfPeriod 348M 272M 241M 357M 140M 396M 259M 302M 168M 112M 271M 220M 344M 190M
cashAtBeginningOfPeriod 272M 202M 259M 140M 396M 251M 271M 168M 112M 271M 344M 171M 190M 116M
operatingCashFlow 228M 102M 595M 158M 65M 130M 390M 212M 180M -125M 339M 99M 257M 229M
capitalExpenditure -13M -13M -38M -8M -12M -11M -28M -8M -7M -9M -17M 0 -23M -11M
freeCashFlow 214M 90M 557M 150M 53M 119M 362M 204M 173M -134M 323M 99M 233M 218M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-10 2024-02-09 2023-02-09 2022-02-11 2021-02-05
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities -127M -467M -177M -130M 4M
netDebtIssuance -309M 0 -279M -100 000 -187M
longTermNetDebtIssuance -309M 0 -279M -100 000 -187M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -178M 65M 45M 28M 29M
netCommonStockIssuance -178M 65M 45M 28M 29M
commonStockIssuance 122M 65M 45M 28M 29M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 0 0
netCashProvidedByFinancingActivities -487M 65M -234M 27M -158M
incomeTaxesPaid 218M 52M 14M 5M 15M
interestPaid 2M 4M 7M 9M 12M

Earning call transcript

2025 q3
2025-10-28 ET (fiscal 2025 q3)
2025 q2
2025-07-30 ET (fiscal 2025 q2)
2025 q1
2025-05-05 ET (fiscal 2025 q1)
2024 q4
2025-02-06 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-01 ET (fiscal 2024 q1)
2023 q4
2024-02-07 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-06 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2026-02-11 16:03 ET
Neurocrine Biosciences reported for 2025 q4
SEC form 8
2026-02-11 16:02 ET
Neurocrine Biosciences published news for 2025 q4
SEC form 8
2026-02-11 16:02 ET
Neurocrine Biosciences published news for 2025 q4
SEC form 10
2025-10-28 20:03 ET
Neurocrine Biosciences reported for 2025 q3
SEC form 8
2025-10-28 20:02 ET
Neurocrine Biosciences published news for 2025 q3
SEC form 8
2025-10-28 20:02 ET
Neurocrine Biosciences reported for 2025 q3
SEC form 10
2025-07-30 20:04 ET
Neurocrine Biosciences reported for 2025 q2
SEC form 8
2025-07-30 20:02 ET
Neurocrine Biosciences published news for 2025 q2
SEC form 8
2025-07-30 20:02 ET
Neurocrine Biosciences reported for 2025 q2
SEC form 10
2025-05-05 00:00 ET
Neurocrine Biosciences reported for 2025 q1
SEC form 8
2025-05-05 00:00 ET
Neurocrine Biosciences published news for 2025 q1
SEC form 8
2025-05-05 00:00 ET
Neurocrine Biosciences reported for 2025 q1
SEC form 10
2025-02-10 00:00 ET
Neurocrine Biosciences published news for 2024 q4
SEC form 8
2025-02-06 16:04 ET
Neurocrine Biosciences published news for 2024 q4
SEC form 8
2025-02-06 16:04 ET
Neurocrine Biosciences reported for 2024 q4
SEC form 10
2024-10-30 07:04 ET
Neurocrine Biosciences reported for 2024 q3
SEC form 8
2024-10-30 07:02 ET
Neurocrine Biosciences published news for 2024 q3
SEC form 8
2024-10-30 07:02 ET
Neurocrine Biosciences reported for 2024 q3
SEC form 10
2024-10-30 00:00 ET
Neurocrine Biosciences reported for 2024 q3
SEC form 10
2024-08-01 07:04 ET
Neurocrine Biosciences reported for 2024 q2
SEC form 8
2024-08-01 07:03 ET
Neurocrine Biosciences published news for 2024 q2
SEC form 8
2024-08-01 07:03 ET
Neurocrine Biosciences reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Neurocrine Biosciences published news for 2024 q2
SEC form 10
2024-05-01 07:03 ET
Neurocrine Biosciences reported for 2024 q1
SEC form 8
2024-05-01 07:01 ET
Neurocrine Biosciences published news for 2024 q1
SEC form 8
2024-05-01 07:01 ET
Neurocrine Biosciences reported for 2024 q1
SEC form 10
2024-05-01 00:00 ET
Neurocrine Biosciences published news for 2024 q1
SEC form 10
2024-02-09 00:00 ET
Neurocrine Biosciences reported for 2023 q4
SEC form 8
2024-02-07 00:00 ET
Neurocrine Biosciences published news for 2023 q4
SEC form 8
2024-02-07 00:00 ET
Neurocrine Biosciences published news for 2023 q4
SEC form 10
2023-10-31 07:02 ET
Neurocrine Biosciences reported for 2023 q3
SEC form 8
2023-10-31 07:01 ET
Neurocrine Biosciences published news for 2023 q3
SEC form 10
2023-10-31 00:00 ET
Neurocrine Biosciences published news for 2023 q3
SEC form 10
2023-08-01 07:03 ET
Neurocrine Biosciences reported for 2023 q2
SEC form 6
2023-08-01 07:02 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 10
2023-08-01 00:00 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 8
2023-08-01 00:00 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 6
2023-07-13 17:26 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 6
2023-07-13 16:05 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 6
2023-07-11 19:04 ET
Neurocrine Biosciences published news for 2023 q2
SEC form 10
2023-05-03 00:00 ET
Neurocrine Biosciences published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Neurocrine Biosciences published news for 2023 q1
SEC form 6
2023-03-28 20:44 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 6
2023-02-23 19:14 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 6
2023-02-15 19:30 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 6
2023-02-10 16:02 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 10
2023-02-09 16:02 ET
Neurocrine Biosciences reported for 2022 q4
SEC form 10
2023-02-09 00:00 ET
Neurocrine Biosciences reported for 2022 q4
SEC form 6
2023-02-06 07:32 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 8
2023-02-06 00:00 ET
Neurocrine Biosciences reported for 2022 q4
SEC form 6
2023-01-09 07:04 ET
Neurocrine Biosciences published news for 2022 q4
SEC form 10
2022-11-01 16:10 ET
Neurocrine Biosciences reported for 2022 q3
SEC form 6
2022-11-01 07:31 ET
Neurocrine Biosciences published news for 2022 q3
SEC form 10
2022-11-01 00:00 ET
Neurocrine Biosciences reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Neurocrine Biosciences reported for 2022 q3
SEC form 6
2022-08-30 08:01 ET
Neurocrine Biosciences published news for 2022 q2
SEC form 10
2022-08-04 16:08 ET
Neurocrine Biosciences reported for 2022 q2
SEC form 6
2022-08-04 16:05 ET
Neurocrine Biosciences published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Neurocrine Biosciences reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Neurocrine Biosciences reported for 2022 q2
SEC form 6
2022-05-31 21:04 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 6
2022-05-24 21:44 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 6
2022-05-23 16:17 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 10
2022-05-04 07:39 ET
Neurocrine Biosciences reported for 2022 q1
SEC form 6
2022-05-04 07:37 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Neurocrine Biosciences reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Neurocrine Biosciences reported for 2022 q1
SEC form 6
2022-04-07 17:16 ET
Neurocrine Biosciences published news for 2022 q1
SEC form 10
2022-02-11 17:11 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 6
2022-02-11 07:31 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 10
2022-02-11 00:00 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 8
2022-02-11 00:00 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 6
2022-02-09 20:01 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 6
2022-01-06 16:08 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 8
2022-01-06 00:00 ET
Neurocrine Biosciences published news for 2021 q4
SEC form 6
2021-12-23 08:00 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 6
2021-12-01 19:56 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 6
2021-11-22 08:01 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 10
2021-11-01 16:05 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 6
2021-11-01 16:03 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 10
2021-11-01 00:00 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 8
2021-11-01 00:00 ET
Neurocrine Biosciences published news for 2021 q3
SEC form 10
2021-08-03 16:03 ET
Neurocrine Biosciences published news for 2021 q2
SEC form 6
2021-08-03 16:02 ET
Neurocrine Biosciences published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Neurocrine Biosciences published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Neurocrine Biosciences published news for 2021 q2
SEC form 6
2021-05-21 16:03 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 10
2021-05-05 16:07 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 6
2021-05-05 16:05 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 6
2021-04-16 16:02 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 6
2021-04-16 09:02 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 6
2021-04-09 17:07 ET
Neurocrine Biosciences published news for 2021 q1
SEC form 10
2021-02-05 16:19 ET
Neurocrine Biosciences published news for 2020 q4
SEC form 6
2021-02-04 16:05 ET
Neurocrine Biosciences published news for 2020 q4
SEC form 6
2021-02-02 16:04 ET
Neurocrine Biosciences published news for 2020 q4
SEC form 6
2021-01-08 07:32 ET
Neurocrine Biosciences published news for 2020 q4
SEC form 6
2020-11-24 08:02 ET
Neurocrine Biosciences published news for 2020 q3
SEC form 6
2020-11-19 08:07 ET
Neurocrine Biosciences published news for 2020 q3
SEC form 10
2020-11-09 16:04 ET
Neurocrine Biosciences published news for 2020 q3
SEC form 6
2020-11-09 16:02 ET
Neurocrine Biosciences published news for 2020 q3